Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Other hematologic neoplasm 2Thoracic 1CNS 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × In Situ Hybridization, Fluorescence × Thoracic × Clear all
NCT00989690 2013-08-12

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
275 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡